Groowe Groowe / Newsroom / EXAS
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

EXAS News

Exact Sciences Corp

Healthcare Quarterly M&A Volume Decreases in Q4:25, According to Acquisition Data from LevinPro HC

globenewswire.com
ABT EXAS

Genomic Testing Market Projected to Reach US$ 41.34 Billion by 2035, Supported by Rising Clinical Oncology Testing Volumes | Astute Analytica

globenewswire.com
NTRA GH EXAS ILMN PACB TXG TMO TWST

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

globenewswire.com
MDXH EXAS

Alamar Biosciences gibt Abschluss der überzeichneten Wandelanleihe-Finanzierung und Erweiterung des Führungsteams bekannt USA - Deutsch USA - Français USA - English APAC - English USA - English USA - čeština

prnewswire.com
AMGN ILMN VRTX RIVN TROW PRGS ALNY REGN GILD BMY MRK ABBV AZN SNY NVS XRAY EVTC MYGN RVTY VTRS BIIB MDLZ PFE SNDX EXAS CRSP NTRA ON IDXX MDT SYK ISRG DXCM COO AMZN GOOG MSFT NVDA IBM INTC QCOM AMD MU ADBE CRM ORCL SAP CSCO ACN HPQ DELL MSCI FIS PAYX ADP BBBY ROST TJX MCHP NXPI SNPS CDNS WDC STX KLAC LRCX AMAT CTAS PAYC NOW DDOG ZS PANW FTNT SNOW PYPL V MA AXP BAC JPM WFC C GS MS SCHW ELAN ZTS ALGN XOM CVX KO PEP MCD DIS CMCSA VZ T NFLX

Halper Sadeh LLC Encourages EXAS, FRGE, TBHC, FFWM Shareholders to Contact the Firm to Discuss Their Rights

globenewswire.com
EXAS FRGE TBHC FFWM

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—FFWM, EXAS, TBHC, and FRGE

globenewswire.com
FFWM EXAS TBHC FRGE

Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

businesswire.com
QTRX ILMN EXAS DGX PFE ARVN

Halper Sadeh LLC Encourages FRGE, EXAS, CIVI, KVUE Shareholders to Contact the Firm to Discuss Their Rights

prnewswire.com
FRGE EXAS CIVI KVUE

Aronora Appoints Industry Leaders to Drive Next Phase of Growth

globenewswire.com
GILD EXAS RLMD

Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight

prnewswire.com
TAK JNJ CANF AMGN ABBV NVS BMY AZN BHC LLY UCB LEO REGN XBI IBB JAZZ MRK SNY GILD INCY PFE LULU PRTH DRH BIIB TEVA ARCT HRMY CRSP NTLA EDIT SNOW DDOG CRM GOOG MSFT AAPL AMZN TSLA NVDA META NFLX DIS CMCSA VZ T KO PEP MCD SBUX HD EXAS ILMN BNTX MRNA XOM CVX BA CAT GE IBM INTC CSCO ADBE QCOM AMAT MU ORCL ACN COST WMT TGT LOW HON GD LMT RTX BAX